The findings suggest that the combination of trastuzumab’s immunologic effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-cell stimulation, with HER2-targeted vaccines or checkpoint inhibitors could offer promising treatment improvements for TNBC [282] as well as other HER2-positive cancers. This evidence concerns the gene ERBB2 and cancer.